Improvements seen in PFS, OS with Dato-DXd for previously untreated, locally recurrent inoperable or metastatic TNBC.
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor treatment. The EPIK-B5 study reported a median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results